Abeona Therapeutics Inc.
ZEVASKYN
recessive dystrophic epidermolysis bullosa (RDEB)
Resolved
433days ago
Approval decision · ~ Apr 30, 2025 estimated
What's at stake
A final FDA approval decision on ZEVASKYN for recessive dystrophic epidermolysis bullosa (RDEB) is expected ~ Apr 30, 2025.
Primary source
· SEC 8-K
verified 17h ago
“due to FDA approval of ZEVASKYN in April of 2025.”